UNSPSC 51314320: Brompheniramine/dextromethorphan/pseudoephedrine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE502. This VA Drug Class (RE502) classifies this compound as belonging to the group ANTIHISTAMINE/DECONGESTANT/ANTITUSSIVE.

UNSPSC 51314320 Brompheniramine/dextromethorphan/pseudoephedrine is a Commodity code that in practice spans a broader range of pharmaceutical and over-the-counter products than its nominal name suggests. State and local governments soliciting under this code are buying generic multi-source pharmaceuticals, OTC products, and specialized health interventions including naloxone kits and drug deactivation systems. The issuing bodies include state health agencies, county health departments, and multistate cooperative purchasing alliances. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, is a standout repeat buyer actively consolidating pharmaceutical procurement across participating state and local facilities. Solicitations require vendors to comply with current Good Manufacturing Practices, Drug Supply Chain Security Act certification, and FDA requirements, and to maintain substantial commercial general liability and professional liability insurance. Contracts typically run two years with optional renewals and include administrative fees (commonly three percent) plus performance penalties for reporting failures or onboarding delays.

Recent activity spans Florida, Texas, and the multistate MMCAP region covering Minnesota and Oregon. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to its Community Health Building and a response deadline of July 26, 2023. The Texas Health and Human Services Commission posted Request for Information HHS0017013 on April 3, 2026 to explore vendor capacity for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager channels. MMCAP issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products with proposals due March 26, 2026 and contract awards effective July 1, 2026; the procurement requires vendors to work through three authorized wholesalers (AmerisourceBergen/Cencara, Cardinal Health, and Morris & Dickson) and weights price competitiveness at 75 percent of the evaluation score.